Crossmark

Pharmacological targeting of actin-dependent dynamin oligomerization ameliorates chronic kidney disease in diverse animal models

Crossref DOI link: https://doi.org/10.1038/nm.3843

Published Online: 2015-05-11

Published Print: 2015-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Schiffer, Mario

Teng, Beina

Gu, Changkyu

Shchedrina, Valentina A

Kasaikina, Marina

Pham, Vincent A https://orcid.org/0000-0001-7083-9360
Hanke, Nils

Rong, Song

Gueler, Faikah

Schroder, Patricia

Tossidou, Irini

Park, Joon-Keun

Staggs, Lynne

Haller, Hermann

Erschow, Sergej

Hilfiker-Kleiner, Denise

Wei, Changli

Chen, Chuang

Tardi, Nicholas

Hakroush, Samy

Selig, Martin K

Vasilyev, Aleksandr

Merscher, Sandra

Reiser, Jochen

Sever, Sanja
License Information

Text and Data Mining valid from 2015-05-11
More Information

Article History

Received: 16 December 2014

Accepted: 18 March 2015

First Online: 11 May 2015

Competing interests

: S.S. and J.R. have pending or issued patents on novel kidney-protective therapies that have been out-licensed to Trisaq Inc. in which they have financial interest. In addition, they stand to gain royalties from their commercialization. The remaining authors report no conflicts.